Safety assessment of niacin in the US Food and Drug Administration's mini‐sentinel system

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Pharmacoepidemiology and Drug Safety

• Publication date

  2018-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/pds.4343PMID 29108128
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sentinel Modular Program for Propensity Score–Matched Cohort Analyses: Application to Glyburide, Glipizide, and Serious Hypoglycemia

  2017cited by this paper
• Successful Comparison of US Food and Drug Administration Sentinel Analysis Tools to Traditional Approaches in Quantifying a Known Drug‐Adverse Event Association

  2016cited by this paper
• Common Models, Different Approaches

  2015cited by this paper
• A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance

  2015cited by this paper
• Effects of extended-release niacin with laropiprant in high-risk patients.

  2014cited by this paper
• The U.S. Food and Drug Administration's Mini‐Sentinel program: status and direction

  2012cited by this paper
• Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

  2012cited by this paper
• An automated database case definition for serious bleeding related to oral anticoagulant use

  2011cited by this paper
• A combined comorbidity score predicted mortality in elderly patients better than existing scores.

  2011cited by this paper
• Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

  2011cited by this paper
• Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects

  2010cited by this paper
• The in vitro effects of niacin on platelet biomarkers in human volunteers

  2010cited by this paper
• Design of a National Distributed Health Data Network

  2009cited by this paper
• Lipid‐modifying efficacy and tolerability of extended‐release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia

  2008cited by this paper
• Safety considerations with niacin therapy.

  2007cited by this paper
• Accuracy of ICD-9-CM Codes for Identifying Cardiovascular and Stroke Risk Factors

  2005cited by this paper
• Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data.

  2001cited by this paper
• Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT).

  2000cited by this paper
• The anti-platelet effect of niceritrol in patients with arteriosclerosis and the relationship of the lipid-lowering effect to the anti-platelet effect.

  1985cited by this paper

• Exploring the Impact of Niacin Intake on Cardiovascular Outcomes: A Comprehensive Analysis Using NHANES Data (2003–2018)

  2024cites this paper
• A review on the efficacy and safety of lipid-lowering drugs in neurodegenerative disease

  2023cites this paper
• Distributed research networks and applications to pragmatic randomized trials

  2021cites this paper
• Outcome misclassification: Impact, usual practice in pharmacoepidemiology database studies and an online aid to correct biased estimates of risk ratio or cumulative incidence

  2020cites this paper
• Drugs that affect lipid metabolism

  2019cites this paper
• Evaluating the Use of Nonrandomized Real‐World Data Analyses for Regulatory Decision Making

  2019cites this paper
• Distributed Networks of Databases Analyzed Using Common Protocols and/or Common Data Models

  2019cites this paper
• Sequential surveillance for drug safety in a regulatory environment

  2018cites this paper
• Cardiovascular outcomes during extended follow-up of the AIM-HIGH trial cohort.

  2018cites this paper